NICE Unified Prioritisation and EMA Regulatory Momentum

MarcusNICE's prioritisation board met for the first time on 29 May. Senior NICE members now maintain oversight of the guidance portfolio through a unified approach. This replaces the fragmented prioritisation processes we've been navigating across different NICE programmes for years.

SaraThe operational shift is significant. Previously, we were managing different timelines and criteria across technology appraisals, diagnostics, and interventional procedures. Now there's centralised decision-making on what gets prioritised and when.

MarcusSimultaneously, they've opened consultation on implementing the EQ-5D-5L value set through their modular update process. This isn't just methodological refinement - it's about making cost-effectiveness calculations more reflective of what matters to people today. More accurate measurements should theoretically improve resource allocation decisions.

SaraBut here's where I push back, Marcus. More accurate measurements don't automatically translate to better decisions if the underlying value judgements remain unchanged. The EQ-5D-5L might capture health states more precisely, but it's still the same utility-based framework. We're optimising the measurement while the fundamental approach to valuing health outcomes stays static.

MarcusThat's fair. The precision improvement might be marginal compared to broader questions about what we're actually measuring. Still, for dossier preparation, this creates immediate practical challenges around which value set to use and how to present sensitivity analyses during the transition period.

SaraExactly. The consultation timeline matters for current submissions. Teams need clarity on implementation dates and whether both value sets will be accepted during transition.

MarcusEMA's CHMP recommended eight medicines for approval at its May meeting. That's substantial regulatory momentum. Jascayd for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis addresses conditions with limited treatment options that cause severe symptoms and death within years of diagnosis.

SaraThe Wegovy extension to include daily oral tablets is strategically more interesting from a market access perspective. The CHMP recommended extending the marketing authorisation as an alternative to weekly injections. This marks the first oral GLP-1 receptor agonist for weight management.

MarcusWhich addresses a major market access barrier. Injectable GLP-1s face adherence challenges and patient preference issues that HTA bodies factor into their assessments. An oral alternative changes the value proposition, especially around long-term effectiveness assumptions.

SaraIt also shifts competitive dynamics. Payers now have leverage between oral and injectable formulations. That creates pricing pressure and opens opportunities for differential reimbursement policies based on patient characteristics or treatment lines.

MarcusThe broader pattern from EMA shows consistent approval activity. Eight medicines in one CHMP meeting suggests the regulatory pipeline remains robust despite economic pressures on R&D investment.

SaraTrue, but regulatory approval is just the starting point for market access. The real test is whether these approvals translate into meaningful patient access across European markets, especially given ongoing HTA capacity constraints.

MarcusThe EU Critical Medicines Act reached political agreement. EMA welcomes this and will work closely with the European Commission and Member States on implementation. The Act builds on regulatory tools from EMA's extended mandate and complements revised EU pharmaceutical legislation.

SaraSupply chain resilience is becoming a market access factor we didn't traditionally consider. EMA's Executive Steering Group on Shortages will conduct supply chain vulnerability assessments to inform policy measures under the new pharmaceutical legislation.

MarcusThis creates new evidence requirements. Companies may need to demonstrate not just clinical and economic value, but also supply security and manufacturing resilience. That's additional dossier complexity.

SaraIt also opens opportunities for companies with robust European manufacturing capabilities to differentiate their value propositions. Supply chain security becomes a competitive advantage in HTA submissions.

MarcusThe Act reinforces manufacturing capacity requirements. This could influence HTA body assessments, especially for critical medicines where supply interruptions carry significant public health risks.

SaraExactly. We might see HTA bodies incorporating supply chain assessments into their broader value frameworks. That's another dimension for evidence planning.

MarcusNICE introduced a collaborative Biosimilar Taskforce in 2025 to coordinate activity across the system and optimise biosimilar uptake. They're targeting aflibercept biosimilars for neovascular age-related macular degeneration as their first focused delivery area.

SaraThis is operationally significant because it moves beyond guidance publication to active implementation support. The taskforce will become a strategic cornerstone of the NICE Whole Lifecycle Approach programme and the 10-Year Health Plan.

MarcusThe lifecycle approach matters for originator manufacturers. NICE isn't just assessing products at launch - they're actively managing the transition to biosimilar competition. That creates ongoing engagement requirements throughout the product lifecycle.

SaraFor biosimilar manufacturers, it provides a structured pathway for uptake support. But it also signals that NICE will be more interventionist in managing competition between originators and biosimilars.

MarcusAflibercept is an interesting test case. It's a high-value, hospital-administered treatment where procurement decisions significantly impact uptake. The taskforce approach could accelerate adoption compared to standard guidance publication.

SaraIt also creates precedent for how NICE might handle future biosimilar transitions. Success with aflibercept could expand this model to other therapeutic areas.

MarcusThe evidence requirements shift from proving biosimilar equivalence to demonstrating system-level implementation strategies.

SaraThese developments point to fundamental changes in how we approach evidence strategy. NICE's unified prioritisation creates more predictable timelines but requires stronger stakeholder intelligence. EMA's approval momentum demands faster market access preparation.

MarcusThe integration of supply chain considerations and active biosimilar implementation shows HTA bodies expanding their operational scope beyond traditional assessment roles. Evidence teams need broader strategic thinking.

SaraBack tomorrow. Show notes at outcomes-analytica.no.